Liberty Health Sciences Inc. moves to OTCQX Market
Dec 04, 2017, 07:00 ET
Market upgrade facilitates industry leading trading experience for U.S. investors
TORONTO, Dec. 4, 2017 /CNW/ - Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) ("Liberty" or the "Company"), an industry leading investor and operator in the U.S. medical cannabis market, announced today that it has qualified to trade on the OTCQX® Best Market, an OTC Markets Group Inc. financial market. Liberty upgraded to OTCQX from the Pink® market.
Liberty begins trading today on OTCQX under the symbol "LHSIF". U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Qualifying to trade on OTCQX Best Market represents an important and exciting milestone for our company as we continue our targeted U.S. expansion," said George Scorsis, CEO and Director of Liberty. "We're committed to offering our growing U.S. investor base an industry leading trading experience and this step helps achieve that goal."
Liberty was sponsored for OTCQX by Sichenzia Ross Ference Kesner LLP, a qualified third-party firm responsible for providing guidance on OTCQX requirements and recommending membership.
"OTCQX companies are distinguished by their commitment to providing a superior trading and information experience for their investors. We look forward to supporting Liberty Health Sciences in the public market," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group Inc.
For more information on Liberty please visit www.libertyhealthsciences.com
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. ("Liberty") is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty's stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's future expansion and growth strategies, the Company's intentions to open dispensary locations in various regions in Florida and the Company's expectations in respect of the future growth of medical cannabis as a treatment option in Florida. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
SOURCE Liberty Health Sciences Inc.
For further information: For Canadian media inquiries, please contact: Matt Salvatore, Edelman, (613) 315-7362, [email protected]; For U.S. media inquiries, please contact: David Schull or Nic Johnson, Russo Partners, (858) 717-2310, [email protected], [email protected]
Share this article